The pharmaceutical company is recognized for its quality in the production of medicines in Brazil and advances in its portfolio. Photo: Igor Baggio.
Prati-Donaduzzi pharmaceutical industry, located in Toledo in the West of Paraná, is among the 10 most innovative companies in the South of the country, according to Amanhã Magazine. In research, the pharmaceutical company is the leader in the Chemical sector and occupies the 10th overall position in the ranking, which lists 25 highlights.
The result obtained by Prati-Donaduzzi shows the constant investments in technology that make the industry of Paraná a benchmark in the production of high quality medicines. Structured advances in Research, Development and Innovation (RD&I) are factors that have ensured this result for the company.
The RD&I Department is focused on incremental innovation and the development of new products. It is an intense work in the search for solutions for diseases of the Central Nervous System. The investment in RD&I is part of a further well-planned strategic planning of the company.
According to the CEO of Prati-Donaduzzi, Eder Fernando Maffissoni, the classification in the ranking highlights the efforts made in recent years. “We are proud of the recognition. This award shows that we are on the right path, combining our growth and the pursuit of excellence with innovation”.
The dimensions of growth and innovation are highlighted through investments that add up to R$ 650 million for the coming years. Among the actions is also the modernization of the industrial park, with the acquisition of new high-tech equipment, the construction of the new Distribution Center and the construction of a new manufacturing facility.
The pharmaceutical company is recognized for its quality in the production of medicines in Brazil and advances in its portfolio. This year, it started in another segment, Medical Prescription and the great leap in this new phase was the launch of Cannabidiol Prati-Donaduzzi, the first product based on 100% Brazilian Cannabis.
Over 22 new branded medications are planned to be launched. Most of them are aimed at the Central Nervous System (CNS) and indicated to treat diseases such as epilepsy, Parkinson's, Alzheimer's, anxiety, depression, neuropathic pain, schizophrenia, autism, bipolar and insomnia. “We are big and we will be even bigger. Currently, we operate with a maximum capacity of 11.5 billion doses per year, but we are betting on technology to grow even more”, explains the CEO.
Champions of Innovation award is in its 16th edition. Photo: Disclosure. Award
The Champions of Innovation award is in its 16th edition and had the participation of several companies from the states of Paraná, Santa Catarina and Rio Grande do Sul. Unlike previous years and due to Covid-19, the award will take place remotely.
The survey questionnaires were processed at the IXL-Center in the United States and resulted in a list of the 50 most innovative companies in the South of the country.